Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Market Capitalization: 1.15 B
The data is delayed by 15 minutes.
ACOR is in the long-term down -61% below S&P in 14 years.
Description: Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company?s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the trea
|Shares Outstanding||46.07 M||EPS||-1.16||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||2.8%||Sales Growth - Q/Q||-15.29%||P/E||-14.87|
|P/E To EPS Growth||P/S||2.74||P/BV||2.1||Price/Cash Per Share||3.83|
|Price/Free Cash Flow||16.48||ROA||1.26%||ROE||2.53%||ROI||1.53%|
|Current Ratio||3.47||Quick Ratio||3.09||Long Term Debt/Equity||0.96||Debt Ratio||0.22|
|Gross Margin||80.15%||Operating Margin||7.54%||Net Profit Margin||3.3%||Dividend Payout Ratio|
|Cash From Financing Activities||4.63 M||Cash From Investing Activities||-116.04 M||Cash From Operating Activities||-9.25 M||Gross Profit||90.84 M|
|Net Profit||1000 K||Operating Profit||5.69 M||Total Assets||1.1 B||Total Current Assets||408.31 M|
|Total Current Liabilities||460.01 M||Total Debt||292.68 M||Total Liabilities||540.27 M||Total Revenue||113.71 M|
|High 52 week||32.6||Low 52 week||13.8||Last close||32.6||Last change||7.24%|
|RSI||96.12||Average true range||1.73||Beta||1.06||Volume||622.39 K|
|Simple moving average 20 days||27.01%||Simple moving average 50 days||34.29%||Simple moving average 200 days||35.16%|
|Performance Week||23.72%||Performance Month||38.14%||Performance Quart||27.34%||Performance Half||57.11%|
|Performance Year||92.9%||Performance Year-to-date||51.98%||Volatility daily||2.78%||Volatility weekly||6.22%|
|Volatility monthly||12.76%||Volatility yearly||44.18%||Relative Volume||329.71%||Average Volume||497.09 K|
|New High||New Low|
2019-03-16 09:30:01 | Acorda ACOR Down 6% Since Last Earnings Report: Can It Rebound?
2019-03-15 17:45:09 | Acorda Therapeutics ACOR Gains But Lags Market: What You Should Know
2019-03-15 15:28:32 | Should You Be Concerned About Acorda Therapeutics, Inc.’s NASDAQ:ACOR ROE?
2019-03-08 07:00:00 | Acorda Therapeutics Announces Management Changes
2019-03-06 07:00:00 | Acorda to Present at Oppenheimer’s 29th Annual Healthcare Conference
2019-03-04 00:00:00 | Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics — What Drives Growth in Today's Competitive Landscape
2019-02-28 16:00:00 | Acorda Therapeutics Announces Commercial Launch of INBRIJA™ levodopa inhalation powder
2019-02-26 07:00:00 | Acorda Therapeutics to Present at Cowen Annual Health Care Conference
2019-02-19 07:00:00 | Acorda Therapeutics to Present at Leerink Global Healthcare Conference
2019-02-18 17:31:12 | Edited Transcript of ACOR earnings conference call or presentation 14-Feb-19 9:30pm GMT
2019-02-15 10:29:03 | Acorda ACOR Q4 Earnings and Revenues Surpass Estimates
2019-02-15 10:02:14 | Acorda Therapeutics ACOR Q4 2018 Earnings Conference Call Transcript
2019-02-14 17:25:10 | Acorda Therapeutics ACOR Tops Q4 Earnings and Revenue Estimates
2019-02-14 16:28:31 | Acorda: 4Q Earnings Snapshot
2019-02-14 16:00:00 | Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2018
2019-02-08 08:03:37 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
2019-02-06 08:40:01 | Array BioPharma ARRY Soars: Stock Adds 11% in Session
2019-02-04 07:00:00 | Acorda Appoints Peter S. Carbone Senior Vice President, Quality
2019-02-01 07:55:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Rexnord, Carlisle Companies, Acorda Therapeutics, Valmont Industries, Reliance Steel & Aluminum, and Thermo Fisher Scientific — New Research Emphasizes Economic Growth
2019-01-31 09:30:02 | Is Acorda Therapeutics ACOR Stock Outpacing Its Medical Peers This Year?
2019-01-29 14:05:54 | Have Insiders Been Selling Acorda Therapeutics, Inc. NASDAQ:ACOR Shares?
2019-01-29 08:02:50 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
2019-01-24 10:46:03 | Vertex Terminates COO Ian Smith on Code of Conduct Violation
2019-01-22 09:31:02 | Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids
2019-01-22 08:39:01 | Aerpio ARPO Jumps: Stock Rises 7.8%
2019-01-15 08:58:01 | Nabriva Therapeutics NBRV Jumps: Stock Rises 6.7%
2019-01-15 08:01:49 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
2019-01-14 09:46:02 | ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
2019-01-14 08:42:01 | Apellis Pharmaceuticals APLS in Focus: Stock Moves 7.1% Higher
2019-01-11 08:01:46 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
2019-01-10 10:00:03 | Acorda ACOR Plans to Launch Inbrija in Q1: What to Expect
2019-01-09 08:39:01 | Mirati Therapeutics MRTX Catches Eye: Stock Jumps 5.4%
2019-01-09 08:01:49 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
2019-01-07 08:46:01 | Myriad Genetics MYGN Catches Eye: Stock Jumps 6.9%
2019-01-07 08:00:00 | Acorda Provides 2018 Highlights and 2019 Guidance at J.P. Morgan Healthcare Conference
2018-12-26 09:47:02 | Company News For Dec 26, 2018
2018-12-26 09:45:51 | Acorda's Prospects Remain Dubious Despite Inbrija Approval, Says Bearish Raymond James
2018-12-26 09:34:02 | Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
2018-12-26 07:30:00 | Biotech News Driving These Companies
2018-12-24 13:30:00 | Why Mindbody, New Gold, and Acorda Therapeutics Jumped Today
2018-12-24 13:11:17 | Biotech Stock Flies After FDA Approves Parkinson's Treatment
2018-12-24 09:41:40 | Acorda Rises 9.7 Percent After FDA Gives Nod for Parkinson's Therapy
2018-12-24 08:59:01 | Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija
2018-12-24 07:20:00 | Acorda Therapeutics' Inbrija Parkinson's disease treatment gets FDA OK